Aster DM Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aster DM Healthcare reported its Q4 and FY25 audited results with an unmodified opinion from Deloitte Haskins & Sells. Standalone revenue from operations grew about 14% YoY to ₹2,320.48 cr in FY25, while Q4 revenue was ₹573.86 cr. Standalone profit for the year jumped to ₹6,208.97 cr (vs ₹156.96 cr last year) and Q4 profit was ₹61.07 cr, but these numbers are heavily boosted by a one-time dividend of ₹5,569.96 cr from its Mauritius subsidiary Affinity after the GCC business separation completed in April 2024. The company also booked ₹372.70 cr as an exceptional gain on preference share redemption, partly offset by ₹49.55 cr of merger-related expenses. Basic EPS for FY25 was ₹124.67. The board recommended a final dividend of ₹1 per share (on top of the ₹4 interim and ₹118 special dividend paid earlier).
Core operating revenue grew steadily, but the headline profit surge is largely a one-off from the GCC business separation and not repeatable. Shareholders will see the final ₹1 dividend, while the completed merger with Quality Care India will reshape the business going forward. The stock is unlikely to react positively to the inflated reported PAT since the real driver is non-operating.